Disclosed are methods of administering 2-methylene-19-nor-(20S)-1a,25- dihydroxyvitamin D3 (2MD) to treat primary hyperparathyroidism or the symptoms of primary hyperparathyroidism in a subject in need thereof. Also disclosed are method of administering 2MD to prevent the symptoms of primary hyperparathyroidism in a subject having primary hyperparathyroidism and at risk for developing symptoms of primary hyperparathyroidism. The methods preferably do not result in raising serum calcium levels in the subject and causing hypercalcemia.
展开▼
